Drug intelligence / Profile preview

dapagliflozin + pioglitazone

Development stage: Unknown
Lead developer: Akums Drugs
Modality: Small Molecules
Administration: Oral

Overview

Dapagliflozin + Pioglitazone is a combination therapy used for the treatment of type 2 diabetes mellitus. **Dapagliflozin** is an SGLT2 inhibitor that blocks glucose reabsorption in the kidneys, promoting glucose excretion through urine. **Pioglitazone** enhances insulin sensitivity by activating PPARγ receptors, improving glucose utilization and reducing insulin resistance. This combination addresses both insulin resistance and excess glucose, providing comprehensive blood sugar control.

Brand names: Gluxit-ProSiena P
Other names: dapagliflozin/pioglitazone

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on dapagliflozin + pioglitazone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dapagliflozin + pioglitazone.

Explore the full profile